What is Infinity Bio?
Founded in 2023, Infinity Bio has rapidly established itself as a pivotal player in the biotechnology sector through its innovative MIPSA technology. By providing high-fidelity antibody profiling, the company addresses a significant gap in immunological research, offering scalable solutions to pharmaceutical enterprises, academic institutions, and the broader biomedical community. Their unique approach to mapping immune responses positions them as a high-authority partner for organizations seeking to accelerate drug discovery and diagnostic development. The company's focus on precision and data-driven insights allows it to maintain a distinct competitive advantage in the rapidly evolving field of proteomics and immune system analysis.
How much funding has Infinity Bio raised?
Infinity Bio has raised a total of $5M across 1 funding round:
Stock/Share Issuance
$5M
Stock/Share Issuance (2025): $5M, investors not publicly disclosed
Key Investors in Infinity Bio
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Infinity Bio?
With this major enterprise-level funding now secured, Infinity Bio is well-positioned to expand its operational footprint and enhance its technological infrastructure. The strategic roadmap likely involves scaling the deployment of their MIPSA platform to meet increasing demand from global pharmaceutical partners. Furthermore, the company is expected to leverage this capital to deepen its research and development efforts, potentially exploring new applications for its antibody profiling technology in clinical diagnostics. By prioritizing long-term growth and scientific excellence, Infinity Bio is set to solidify its role as an essential component of the modern biomedical research ecosystem, driving advancements that could redefine standard practices in immune system monitoring and therapeutic development.
See full Infinity Bio company page
